EXPORT CITATION

Chapter-09 History of ACE-Inhibitors

BOOK TITLE: Textbook of Cardiology (A Clinical & Historical Perspective)

Author
1. Sawhney JPS
ISBN
9789350900819
DOI
10.5005/jp/books/12259_9
Edition
1/e
Publishing Year
2013
Pages
3
Author Affiliations
1. Sir Ganga Ram Hospital, New Delhi, India, Sir Gangaram Hospital, New Delhi, India, Dharma Vira Heart Center, Sir Ganga Ram Hospital, New Delhi, India
Chapter keywords
ACE-inhibitors, renal disease, ventricle hypertrophy, systemic arterial hypertension, circulating vasopressor substance, dialysate, hypertension

Abstract

This chapter discusses history of ACE-inhibitors. The first observation linking renal disease to left ventricle hypertrophy was reported by Richard Bright in 1836. He related hypertrophy to an increased resistance to blood flow in the small vessels because of the altered condition of the blood. The relationship between development of systemic arterial hypertension (HTN) and pathological changes in the kidney were hypothesized for many years, with Franz Volhard suggesting existence of a circulating vasopressor substance. The first step in the development of ACE-inhibitors (ACEI) was the discovery of ACE in plasma by Leonard T Skeggs and his colleagues in 1956. They showed that the dialysate of plasma from patients with malignant HTN contained hypertensin, but only some patients with essential benign HTN had hypertensin in the plasma. The history and development of ACEIs reflects the efforts of basic and drug-oriented research and example of the relationship between university and industry research. Clinical research and drug discovery have always been closely associated, more importantly, because clinical research often indicates new areas in which drug discovery could be profitable.

Related Books

© 2019 Jaypee Brothers Medical Publishers (P) LTD.   |   All Rights Reserved